Document is current

Article History

Received: 7 August 2020

Accepted: 11 February 2021

First Online: 20 March 2021

Ethics approval and consent to participate

: The study was reviewed by the research ethics board at the Centre for Addiction and Mental Health (approval number: 065/2016). Patient consent for participation in the STOP smoking cessation programme was obtained at the time of enrollment.

: Not applicable.

: The authors declare that they have no competing interests concerning this manuscript. However, some authors have general disclosures to report. PS reports receiving grants and /or research support from the Centre for Addiction and Mental Health, Health Canada, Ontario Ministry of Health and Long-term care (MOHLTC), Canadian Institutes of Health Research (CIHR) , Canadian Centre on Substance Use and Addiction, Public Health Agency of Canada (PHAC), Ontario Lung Association, Medical Psychiatry Alliance, Extensions for Community Healthcare Outcomes, Canadian Cancer Society Research Institute (CCSRI), Cancer Care Ontario, Ontario Institute for Cancer Research, Ontario Brain Institute, McLaughlin Centre, Academic Health Sciences Centre, Workplace Safety and Insurance Board, National Institutes of Health (NIH), and the Association of Faculties of Medicine of Canada. PS also reports receiving funding and/or honoraria from the following commercial organisations: Pfizer Inc./Canada, Shoppers Drug Mart, Bhasin Consulting Fund Inc., Patient-Centered Outcomes Research Institute, ABBVie and Bristol-Myers Squibb. Further, PS reports receiving consulting fees from Pfizer Inc./Canada, Evidera Inc., Johnson & Johnson Group of Companies, Medcan Clinic, Inflexxion Inc., V-CC Systems Inc., MedPlan Communications, Kataka Medical Communications, Miller Medical Communications, Nvision Insight Group and Sun Life Financial. Through an open tender process, Johnson & Johnson, Novartis, and Pfizer Inc. are vendors of record for providing smoking cessation pharmacotherapy, free or discounted, for research studies in which PS is the principal investigator or co-investigator. NM and LZ report receiving grant funding from CIHR, CCSRI, Ontario MOHLTC and Pfizer Inc/Canada. All remaining authors declare that they have no competing interests.